Study Says Ozempic Knockoffs Could Cost $3 [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Novo Nordisk ( NYSE:NVO may soon face much cheaper competition for its blockbuster GLP -1 drugs after a new study suggested generic versions of semaglutide , the active ingredient in Ozempic and Wegovy , could cost under $3 per month to manufacture. Warning! GuruFocus has detected 2 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Researchers examined 20242025 shipment records tied to semaglutide and added estimates for formulation, packaging, taxes, and profit margins. Based on those inputs, the study estimates injectable generic semaglutide could cost between $28 and $140 per year per patient , while oral versions could range from $186 to $380 annually The findings come as Novo Nordisk prepares for growing generic competition in markets such as India, China, Brazil, Canada, and Turkey , where semaglutide patents are beginning to expire. Recommended Stories
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Reframing The Novo Nordisk (CPSE:NOVO B) Narrative As Analysts Reset Expectations And Valuation [Yahoo! Finance]Yahoo! Finance
- Drugmaker Aspen plans Africa weight-loss drug push [Yahoo! Finance]Yahoo! Finance
- CagriSema Incident: The Surprise Winner And What It Means For The Novo-Lilly Rivalry [Seeking Alpha]Seeking Alpha
- Novo Nordisk (NVO) Reports 10% Sales Growth as Obesity Care Hits DKK 82B [Yahoo! Finance]Yahoo! Finance
- Zealand's stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics' [CNBC]CNBC
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/2/26 - Form 6-K
- 3/2/26 - Form 6-K
- 2/23/26 - Form 6-K
- NVO's page on the SEC website